Lupin Pharmaceuticals Inc. has recalled 40,824 bottles of Cefdinir powder for Oral Suspension USP, 250 mg/5 mL, which is a prescription antibiotic (generic Omnicef). The recall was initiated because the drug was found to be superpotent, meaning it contains more of the active ingredient than specified. Taking a higher dose than intended could lead to unintended side effects or toxicity, especially in pediatric patients. The affected products were distributed nationwide in 60 mL and 100 mL bottles and should be returned to the pharmacy.
The product is superpotent, containing levels of Cefdinir that exceed the labeled dosage. This could result in patients receiving a higher-than-prescribed dose, potentially increasing the risk of adverse reactions or complications associated with the medication.
Drug recall baseline remedy
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.